TRX Tissue Regenix Group

Hardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth

Hardman & Co Research
Hardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth

10-Apr-2024 / 07:15 GMT/BST
The issuer is solely responsible for the content of this announcement.

Hardman & Co Research on Tissue Regenix (TRX):

Six consecutive periods of >20% growth

 

TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets. Investment in tissue processing, manufacturing capacity and strong commercial partners, together with its “4S” strategy, has generated six consecutive reporting periods of strong growth, with TRX turning EBITDA-positive in 2023. New growth in 2024 will deliver a fully profitable, cash-generative, group. The cash will be invested to expand capacity even further through Phase 2, starting in 2025.

 

Please click on the link below for the full report:

If you are interested in meeting the company, you can register your interest by clicking on the above link.

To contact us:

Hardman & Co

9 Bonhill Street

London

EC2A 4DJ

Follow us on Twitter @HardmanandCo

Contact:

Martin Hall


 

 



 

Hardman & Co Research can still be accessed for free after MiFID II. Please to read the statement.

About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service

1876877  10-Apr-2024 

fncls.ssp?fn=show_t_gif&application_id=1876877&application_name=news&site_id=research_pool
EN
10/04/2024

Underlying

TRXTissue Regenix Group

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tissue Regenix Group

 PRESS RELEASE
Free
TRX Tissue Regenix ...

Hardman & Co Research on Tissue Regenix (TRX): Six consecutive period...

Hardman & Co Research Hardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth 10-Apr-2024 / 07:15 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth   TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets. Investment in tissue processing, ma...

April 10, 2024 1 EN
TRX Tissue Regenix ...
KMK KROMEK GROUP ... (+10)

Hybridan Small Cap Feast - 25 Jan 24

25th January 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obje...

TRX TISSUE REGENIX GROUP
KMK KROMEK GROUP
EPWN EPWIN GROUP
ALNOV NOVACYT SAS
RDT ROSSLYN DATA TECHNOLOGIES
PEG PETARDS GROUP PLC
NMT NEOMETALS
SBTX SKINBIOTHERAPEUTICS
JSE JADESTONE ENERGY
TISSUE REGENIX GROUP PLC
01/25/24 January 25, 2024 1 EN
Martin Hall
  • Martin Hall
SN. SMITH & NEPHEW ...
AGL ANGLE PLC ... (+54)

Hardman & Co Healthcare Index: 2023 – Capital demands dent performance

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (...

SN. SMITH & NEPHEW PLC
AGL ANGLE PLC
DEMG DELTEX MEDICAL GROUP PLC
TSTL TRISTEL PLC
TRX TISSUE REGENIX GROUP
EKF EKF DIAGNOSTICS HOLDINGS
ETX E-THERAPEUTICS
AVCT AVACTA GROUP
PHP PRIMARY HEALTH PROPERTIES PLC
AGY ALLERGY THERAPEUTICS PLC
APH ALLIANCE PHARMA PLC
AVO ADVANCED ONCOTHERAPY
OXB OXFORD BIOMEDICA PLC
ALNOV NOVACYT SAS
VLG VENTURE LIFE GROUP
SN/ IMMUPHARMA
IMM PROTEOME SCIENCES PLC
PRM GENUS PLC
GNS SURGICAL INNOVATIONS GROUP PLC
SUN ADVANCED MEDICAL SOLUTIONS GROUP PLC
AMS OXFORD METRICS
OMG ECO ANIMAL HEALTH GROUP
EAH SDI GROUP
SDI HVIVO
HVO INDIVIOR PLC
INDV VALIRX
VAL SHIELD THERAPEUTICS
STX SYNAIRGEN PLC
SNG IP GROUP
IPO SCANCELL HOLDINGS
SCLP SYNCONA
SYNC ERGOMED
ERGO SPIRE HEALTHCARE GROUP PLC
SPI REDX PHARMA
REDX ASSURA PLC
AGR GENEDRIVE
GDR SPIRE INC
SR CONVATEC GROUP PLC
CTEC DESTINY PHARMA
DEST RENEURON GROUP
RENE IXICO
IXI 10X GENOMICS INC CLASS A
TXG INDIVA LTD
NDVA IMMUNOCORE HOLDINGS ADS
IMCR 2SEVENTY BIO INC
TSVT OXFORD NANOPORE TECHNOLOGIES PLC
ONT SILENCE THERAPEUTICS PLC
SLN SAREUM HOLDINGS PLC
SAR BENEVOLENTAI
BAI 123FAHRSCHULE SE
123F 1895 BANCORP OF WISCONSIN INC
BCOW TISSUE REGENIX GROUP PLC
PLP.H 3D SIGNATURES INC
Z29 029 GROUP SE
01/12/24 January 12, 2024 1 EN
Martin Hall
  • Martin Hall
TRX Tissue Regenix ...
TISSUE REGENIX ...

Hardman & Co Research: Tissue Regenix (TRX) - Continuing postive momen...

TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics and dental markets. 1H’23 results highlighted the benefits and efficiencies being derived from investment and reorganisation in manufacturing capacity, with the first underlying EBITDA-positive reporting period. With further strong growth forecast ...

TRX TISSUE REGENIX GROUP
TISSUE REGENIX GROUP PLC
09/18/23 September 18, 2023 1 EN
 PRESS RELEASE
Free
TRX Tissue Regenix ...

Hardman & Co Research on Tissue Regenix (TRX): Continuing postive mome...

Hardman & Co Research Hardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H'23 18-Sep-2023 / 10:40 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Tissue Regenix (TRX): Continuation of the positive momentum   TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics and dental markets. 1H’23 results highli...

September 18, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch